Aliases & Classifications for Gynecomastia

MalaCards integrated aliases for Gynecomastia:

Name: Gynecomastia 12 73 29 54 6 15 70

Classifications:



External Ids:

Disease Ontology 12 DOID:12698
MeSH 44 D006177
NCIt 50 C3073
SNOMED-CT 67 155963008
ICD10 32 N62
UMLS 70 C0018418

Summaries for Gynecomastia

Disease Ontology : 12 A disorder of sexual development that is characterized by enlargement or swelling of male breast tissue resulting from elevated male estrogen levels or imbalanced estrogen and testosterone levels.

MalaCards based summary : Gynecomastia is related to androgen insensitivity, partial and aromatase excess syndrome. An important gene associated with Gynecomastia is HSD17B3 (Hydroxysteroid 17-Beta Dehydrogenase 3), and among its related pathways/superpathways are Prolactin Signaling Pathway and Translation Non-genomic (rapid) action of Androgen Receptor. The drugs Anastrozole and Bicalutamide have been mentioned in the context of this disorder. Affiliated tissues include breast, prostate and testis, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Wikipedia : 73 Gynecomastia (also spelled Gynaecomastia),[a] is the abnormal non-cancerous enlargement of one or both... more...

Related Diseases for Gynecomastia

Diseases related to Gynecomastia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 510)
# Related Disease Score Top Affiliating Genes
1 androgen insensitivity, partial 31.9 SRD5A1 SHBG CYP19A1 AR
2 aromatase excess syndrome 31.5 SHBG POMC PGR GNRH1 ESR2 ESR1
3 hypogonadotropic hypogonadism 31.5 SHBG PRL GNRH1 CYP19A1 AR
4 in situ carcinoma 30.9 PGR ESR1 CYP19A1
5 hypogonadism 30.8 SHBG PRL GNRH1 AR
6 androgen insensitivity syndrome 30.8 SRY SRD5A2 SRD5A1 SHBG HSD17B3 CGA
7 hyperthyroidism 30.6 SHBG PRL POMC CGA
8 ductal carcinoma in situ 30.6 PGR ESR2 ESR1 CYP19A1 AR
9 leydig cell tumor 30.6 PRL INHA GNRH1 CYP19A1
10 sertoli cell tumor 30.6 PGR INHA CYP19A1 AR
11 breast fibroadenoma 30.4 PGR ESR1 CYP19A1 AR
12 hyperprolactinemia 30.4 SHBG PRL POMC GNRH1
13 mammary paget's disease 30.2 PGR ESR1 AR
14 nipple carcinoma 30.2 PGR ESR1
15 seminoma 30.1 INHA ESR2 CGB5 CGA
16 intracystic papillary adenoma 30.0 PRL PGR ESR1
17 sweat gland cancer 30.0 PGR ESR1 AR
18 breast cyst 30.0 PRL KLK3 CYP19A1
19 breast carcinoma in situ 30.0 PGR ESR1 CYP19A1
20 lobular neoplasia 30.0 PGR ESR2 ESR1
21 acne 29.9 SRD5A1 SHBG PRL POMC AR
22 prostatic adenoma 29.9 SRD5A1 SHBG PRL KLK3 AR
23 alopecia 29.8 SRD5A2 SRD5A1 SHBG PRL AR
24 breast disease 29.8 SHBG PRL POMC PGR KLK3 ESR2
25 testicular cancer 29.8 SHBG GNRH1 CYP3A4 CGB5 CGA AR
26 gonadal dysgenesis 29.8 SRY SHBG CGB5
27 estrogen excess 29.8 SHBG PRL PGR GNRH1 ESR2 ESR1
28 prostatic hyperplasia, benign 29.8 SRD5A2 SRD5A1 KLK3 AR
29 adrenal cortical carcinoma 29.8 POMC INHA CYP19A1
30 hypospadias 29.8 SRY SRD5A2 SRD5A1 HSD17B3 ESR2 ESR1
31 female breast cancer 29.7 PGR KLK3 ESR1 CYP19A1 AR
32 anxiety 29.7 PRL POMC ESR1 CYP3A4
33 pseudohermaphroditism 29.7 SRY SRD5A2 SRD5A1 POMC HSD17B3 CYP19A1
34 varicocele 29.7 SHBG PRL GNRH1 CGA AR
35 testicular germ cell cancer 29.7 ESR2 ESR1 CYP3A4 AR
36 pituitary adenoma, prolactin-secreting 29.6 PRL POMC GNRH1 ESR2 ESR1
37 transsexualism 29.6 SRD5A2 ESR2 CYP19A1 AR
38 hermaphroditism 29.6 SRY SRD5A2 SHBG CGA AR
39 hypothyroidism 29.6 SHBG PRL POMC GNRH1 CGA
40 ovarian cyst 29.5 PRL GNRH1 ESR2 CYP19A1
41 oligospermia 29.5 SRD5A2 PRL GNRH1 AR
42 complete androgen insensitivity syndrome 29.5 SRY SHBG CYP19A1 CGA AR
43 impotence 29.5 SRD5A1 SHBG PRL POMC KLK3 GNRH1
44 germ cell cancer 29.5 ESR2 ESR1 CYP3A4 CGA AR
45 alopecia, androgenetic, 1 29.4 SRD5A2 SRD5A1 SHBG CYP19A1 AR
46 lipoid congenital adrenal hyperplasia 29.4 SRD5A1 POMC GNRH1 CYP19A1
47 prostate disease 29.4 SRD5A2 SRD5A1 KLK3 CYP19A1 AR
48 acromegaly 29.4 SHBG PRL POMC GNRH1
49 leiomyoma 29.4 PGR GNRH1 ESR2 ESR1 CYP19A1
50 pituitary gland disease 29.3 PRL POMC GNRH1 CGA

Graphical network of the top 20 diseases related to Gynecomastia:



Diseases related to Gynecomastia

Symptoms & Phenotypes for Gynecomastia

MGI Mouse Phenotypes related to Gynecomastia:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.34 AR CGA CYP19A1 ESR1 ESR2 GNRH1
2 homeostasis/metabolism MP:0005376 10.27 AR CGA CYP19A1 ESR1 ESR2 GNRH1
3 hematopoietic system MP:0005397 10.26 AR CYP19A1 ESR1 ESR2 GNRH1 HSD17B3
4 immune system MP:0005387 10.21 AR CYP19A1 ESR1 ESR2 GNRH1 HSD17B3
5 integument MP:0010771 10.06 AR CYP19A1 ESR1 ESR2 GNRH1 PGR
6 adipose tissue MP:0005375 10.05 AR CYP19A1 ESR1 ESR2 HSD17B3 PHF6
7 liver/biliary system MP:0005370 9.97 AR CYP19A1 ESR1 ESR2 GNRH1 INHA
8 muscle MP:0005369 9.92 AR CYP19A1 ESR1 ESR2 HSD17B3 KLK3
9 neoplasm MP:0002006 9.91 AR ESR1 ESR2 GNRH1 INHA PGR
10 nervous system MP:0003631 9.9 AR CGA CYP19A1 ESR1 ESR2 GNRH1
11 renal/urinary system MP:0005367 9.56 AR CYP19A1 ESR1 ESR2 GNRH1 HSD17B3
12 reproductive system MP:0005389 9.44 AR CGA CYP19A1 ESR1 ESR2 GNRH1

Drugs & Therapeutics for Gynecomastia

Drugs for Gynecomastia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 28)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
2
Bicalutamide Approved Phase 3 90357-06-5 2375 56069
3
Tamoxifen Approved Phase 3 10540-29-1 2733526
4
Nitroglycerin Approved, Investigational Phase 3 55-63-0 4510
5 Hormone Antagonists Phase 3
6 Antineoplastic Agents, Hormonal Phase 3
7 Estrogens Phase 3
8 Estrogen Receptor Antagonists Phase 3
9 Hormones Phase 3
10 Estrogen Antagonists Phase 3
11 Aromatase Inhibitors Phase 3
12 Androgen Antagonists Phase 3
13 Androgens Phase 3
14 Estrogen Receptor Modulators Phase 3
15 Vasodilator Agents Phase 3
16
Dexamethasone Approved, Investigational, Vet_approved 50-02-2 5743
17
Dexamethasone acetate Approved, Investigational, Vet_approved 1177-87-3
18
Bupivacaine Approved, Investigational 2180-92-9, 38396-39-3 2474
19
Epinephrine Approved, Vet_approved 51-43-4 5816
20
Racepinephrine Approved 329-65-7 838
21
Lidocaine Approved, Vet_approved 137-58-6 3676
22
Vitamin A Approved, Nutraceutical, Vet_approved 68-26-8, 11103-57-4 445354
23 Hemostatics
24 Anesthetics, Local
25 Anesthetics
26 Epinephryl borate
27 retinol
28 Retinol palmitate

Interventional clinical trials:

(show all 11)
# Name Status NCT ID Phase Drugs
1 A Comparative Trial of the Efficacy of Two Different Nolvadex (NDX) Dosing and Scheduling Regimens in Preventing Gynecomastia Induced by Casodex (CDX) 150 Monotherapy in Prostate Cancer Patients. An Open, Multicenter, Phase III Trial. Completed NCT00233610 Phase 3 Bicalutamide;Tamoxifen
2 An OptioExtension of Trial 1033US/0006 to Assess Safety, Tolerability, Efficacy of Anastrozole (ZD1033, Arimidex™) in Treatment of Gynecomastia in Pubertal Boys Given Placebo and to Conduct a Long-Term Safety Follow-Up of Non-Responding Subjects Given Anastrozole in the Previous Trial Completed NCT00637182 Phase 3 Anastrozole
3 Topical Nitroglycerin as a Mechanism for Cutaneous Vaso-modulation and Improved Wound Healing After Breast Reduction Recruiting NCT04321967 Phase 3 Nitroglycerin Paste;Dermabond
4 An Open-Label Pharmacokinetic and Pharmacodynamic Study of Anastrozole (Arimidex™) Used to Treat Pubertal Boys With Gynecomastia of Recent Onset Completed NCT00241436 Phase 2 Anastrozole (ARIMIDEX™)
5 Randomised, Double-blind, Placebo Controlled, Parallel-group, Multicentre Phase II Study to Assess Dose Response Relationship of Nolvadex (Oral Tablet) in Prophylactic Treatment of Gynaecomastia and Breast Pain Associated With CASODEX 150 mg (Oral Tablet), and to Assess the Tumour Control….. Completed NCT00637871 Phase 2 Casodex;Tamoxifen
6 Targeted Fat Reduction of Pseudogynecomastia in the Male Breast Using the ZELTIQ Coolsculpting System Unknown status NCT01791660
7 A Randomized Controlled Trial Modified Benelli Procedure For Subcutaneous Mastectomy In Gynecomastia Completed NCT04063722
8 Ultrasound Guided Modified Pectoral Plane (PECS II )Block Versus Erector Spinae Plane (ESP) Block for Perioperative Analgesia of Surgical Treatment of Gynecomastia Completed NCT04221074
9 Post-massive Weight Loss Chest Contouring: Inferior Pedicle Technique in Pseudo-gynecomastia Correction Completed NCT03319862
10 Thoracic Interfascial Plane Block Versus Thoracic Paravertebral Block for Anesthesia in Gynecomastia Surgery: A Randomized Controlled Trial Recruiting NCT04425447 Tumescent local anesthesia;Thoracic paravertebral block;Thoracic interfascial plane block
11 Clinical Evaluation of the UltraShape Device for Non-Invasive Fat Reduction in the Male Breast (Pseudogynecomastia) Withdrawn NCT02711605

Search NIH Clinical Center for Gynecomastia

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Tamoxifen
Tamoxifen Citrate

Genetic Tests for Gynecomastia

Genetic tests related to Gynecomastia:

# Genetic test Affiliating Genes
1 Gynecomastia 29

Anatomical Context for Gynecomastia

MalaCards organs/tissues related to Gynecomastia:

40
Breast, Prostate, Testis, Liver, Heart, Pituitary, Skin

Publications for Gynecomastia

Articles related to Gynecomastia:

(show top 50) (show all 3229)
# Title Authors PMID Year
1
[The use of aromatase inhibitors in children]. 61 54
20088436 2009
2
Venlafaxine-induced gynecomastia in a young patient: a case report. 54 61
18978497 2009
3
Mineralocorticoid receptor antagonists and endothelial function. 61 54
18729003 2008
4
Effect of hyperprolactinemia during development in children and adolescents. 61 54
18816151 2008
5
Gynecomastia in prepubertal and pubertal men. 61 54
18622206 2008
6
An open label, dose response study to determine the effect of a dietary supplement on dihydrotestosterone, testosterone and estradiol levels in healthy males. 61 54
18700016 2008
7
Association between gynecomastia and aromatase (CYP19) polymorphisms. 61 54
18426832 2008
8
[Phenotype of patients with gynecomastia]. 54 61
18465688 2008
9
Growth hormone producing prolactinoma in juvenile cystinosis: a simple coincidence? 54 61
17638022 2008
10
Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. 54 61
18004132 2007
11
Regional rearrangements in chromosome 15q21 cause formation of cryptic promoters for the CYP19 (aromatase) gene. 54 61
17584767 2007
12
Effect of hyperprolactinemia in male patients consulting for sexual dysfunction. 61 54
17655655 2007
13
Gynecomastia: review. 61 54
17925790 2007
14
Gynecomastia. 54 61
17543732 2007
15
Open-label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavioral disorders. 61 54
16865035 2006
16
Risperidone-induced symptomatic hyperprolactinaemia in adolescents. 61 54
16633146 2006
17
Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor. 54 61
16452534 2006
18
Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. 54 61
16280763 2005
19
Leptin levels in boys with pubertal gynecomastia. 61 54
16355805 2005
20
[Aromatase-dependent gynecomastia in a patient with adenocarcinoma of the lung]. 54 61
16238933 2005
21
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. 61 54
15681525 2005
22
Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone. 61 54
15947469 2005
23
Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred. 61 54
15483104 2005
24
Possible involvement of aromatase overexpression induced by cyclo-oxygenase-2 in the pathogenesis of idiopathic gynecomastia. 61 54
16392624 2005
25
The effect of tamoxifen on sex hormone binding globulin in adolescents with pubertal gynecomastia. 54 61
15379424 2004
26
Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. 54 61
15238910 2004
27
Gynecomastia due to hormone therapy for advanced prostate cancer: a report of ten surgically treated cases and a review of treatment options. 54 61
15510985 2004
28
[Sexual dysfunction among 78 Moroccan male hemodialysis patients: clinical and endocrine study]. 54 61
15277975 2004
29
Multiple structural and functional abnormalities in the p450 aromatase expressing transgenic male mice are ameliorated by a p450 aromatase inhibitor. 54 61
14982857 2004
30
Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole. 54 61
14963480 2004
31
Differential expressions of BRCA1 and BRCA2 in infantile gynecomastia. 61 54
15015615 2004
32
CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding. 54 61
14504283 2003
33
Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. 54 61
12736278 2003
34
Gynecomastia attributable to human chorionic gonadotropin-secreting giant cell carcinoma of lung. 61 54
12917067 2003
35
Switch to quetiapine in antipsychotic agent-related hyperprolactinemia. 61 54
12522680 2002
36
On the inhibitory action of 29 drugs having side effect gynecomastia on estrogen production. 54 61
12477487 2002
37
[An elderly case of advanced gastric cancer with gynecomastia and high serum levels of hCG]. 54 61
12404754 2002
38
Gynecomastia with sulpiride. 61 54
11846864 2002
39
Effects of risperidone on gonadal axis hormones in schizophrenia. 61 54
11793612 2001
40
Sertoli cell proliferations of the infantile testis: an intratubular form of Sertoli cell tumor? 61 54
11688457 2001
41
Measurement of androgen and estrogen receptors in breast tissue from subjects with anabolic steroid-dependent gynecomastia. 54 61
11554608 2001
42
Occult Leydig cell tumor in a patient with gynecomastia. 54 61
11497478 2001
43
Pituitary prolactin-secreting macroadenoma combined with bilateral breast cancer in a 45-year-old male. 61 54
11434671 2001
44
Aromatase expression in the human male. 54 61
11403890 2001
45
Overexpression of aromatase in transgenic male mice results in the induction of gynecomastia and other biochemical changes in mammary glands. 61 54
11358670 2001
46
[De La Chapelle syndrome]. 61 54
11268892 2001
47
Estrogen and progesterone receptors in gynecomastia. 54 61
11039372 2000
48
Immunohistochemical localization of prostate-specific antigen in ductal epithelium of male breast. Potential diagnostic pitfall in patients with gynecomastia. 61 54
10937064 2000
49
Serum inhibin B concentration in a prepubertal boy with gynecomastia and Peutz-Jeghers syndrome. 61 54
10689645 2000
50
Aromatase and gynecomastia. 54 61
10731125 1999

Variations for Gynecomastia

ClinVar genetic disease variations for Gynecomastia:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 KIF4A NM_012310.5(KIF4A):c.1553G>C (p.Arg518Pro) SNV Uncertain significance 523498 rs766819113 GRCh37: X:69573536-69573536
GRCh38: X:70353686-70353686

Expression for Gynecomastia

Search GEO for disease gene expression data for Gynecomastia.

Pathways for Gynecomastia

Pathways related to Gynecomastia according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.34 PRL ESR2 ESR1 CGA
2
Show member pathways
12.16 SRD5A2 SRD5A1 KLK3 AR
3
Show member pathways
12.07 POMC INHA CGB5 CGA
4
Show member pathways
11.8 PRL PGR ESR1
5 11.73 ESR2 ESR1 AR
6
Show member pathways
11.71 ESR1 CGB5 CGA
7 11.64 PRL POMC CGA
8
Show member pathways
11.61 PGR NR3C2 ESR2 ESR1 AR
9 11.51 GNRH1 ESR2 CGA
10
Show member pathways
11.4 HSD17B3 CYP3A4 CYP19A1
11 11.35 SRY KLK3 AR
12 11.32 CYP3A4 CYP19A1 CGA AR
13
Show member pathways
11.3 KLK3 ESR1 AR
14
Show member pathways
11.18 SRD5A2 SRD5A1 HSD17B3 CYP3A4 CYP19A1
15 11.13 PGR INHA ESR2 CYP19A1
16
Show member pathways
11 SRD5A2 SRD5A1 POMC HSD17B3 CYP19A1 CGA
17
Show member pathways
10.93 SRD5A2 SRD5A1 HSD17B3
18 10.84 SHBG GNRH1 AR
19 10.67 GNRH1 CGA
20 9.93 ESR2 ESR1 CYP19A1

GO Terms for Gynecomastia

Cellular components related to Gynecomastia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 organelle membrane GO:0031090 8.92 SRD5A2 SRD5A1 CYP3A4 CYP19A1

Biological processes related to Gynecomastia according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.18 PHF6 PGR NR3C2 ESR2 ESR1 CGB5
2 signal transduction GO:0007165 10.14 PRL POMC PGR NR3C2 INHA GNRH1
3 positive regulation of transcription by RNA polymerase II GO:0045944 10.1 SRY POMC PGR ESR2 ESR1 CGA
4 transcription initiation from RNA polymerase II promoter GO:0006367 9.83 PGR NR3C2 ESR2 ESR1 AR
5 male gonad development GO:0008584 9.72 SRD5A2 SRD5A1 INHA ESR1 AR
6 cellular response to estradiol stimulus GO:0071392 9.7 SRD5A1 ESR2 ESR1
7 sex differentiation GO:0007548 9.67 SRY SRD5A2 SRD5A1
8 intracellular estrogen receptor signaling pathway GO:0030520 9.65 ESR2 ESR1 AR
9 steroid biosynthetic process GO:0006694 9.65 SRD5A2 SRD5A1 HSD17B3 CYP3A4 CYP19A1
10 male genitalia development GO:0030539 9.63 SRD5A2 SRD5A1 HSD17B3
11 regulation of systemic arterial blood pressure GO:0003073 9.59 KLK3 AR
12 male sex determination GO:0030238 9.58 SRY GNRH1
13 cellular response to testosterone stimulus GO:0071394 9.57 SRD5A1 AR
14 cell-cell signaling GO:0007267 9.56 SRD5A2 POMC PGR INHA GNRH1 ESR2
15 testosterone biosynthetic process GO:0061370 9.55 SRD5A2 HSD17B3
16 androgen catabolic process GO:0006710 9.54 SRD5A1 CYP19A1
17 androgen biosynthetic process GO:0006702 9.54 SRD5A2 SRD5A1 HSD17B3
18 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.51 PGR AR
19 androgen metabolic process GO:0008209 9.46 SRD5A2 SRD5A1 ESR1 CYP3A4
20 intracellular steroid hormone receptor signaling pathway GO:0030518 9.02 PGR NR3C2 ESR2 ESR1 AR

Molecular functions related to Gynecomastia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.99 SRY PGR NR3C2 ESR2 ESR1 AR
2 sequence-specific DNA binding GO:0043565 9.93 PGR NR3C2 ESR2 ESR1 AR
3 enzyme binding GO:0019899 9.85 PHF6 PGR ESR2 ESR1 CYP3A4 AR
4 lipid binding GO:0008289 9.8 SHBG PGR NR3C2 ESR2 ESR1 AR
5 ATPase binding GO:0051117 9.72 PGR ESR1 AR
6 steroid hormone receptor activity GO:0003707 9.56 PGR NR3C2 ESR2 ESR1
7 nuclear receptor activity GO:0004879 9.55 PGR NR3C2 ESR2 ESR1 AR
8 RNA polymerase II transcription coactivator binding GO:0001225 9.52 PGR AR
9 estrogen receptor activity GO:0030284 9.49 ESR2 ESR1
10 androgen binding GO:0005497 9.48 SHBG AR
11 3-oxo-5-alpha-steroid 4-dehydrogenase activity GO:0003865 9.46 SRD5A2 SRD5A1
12 cholestenone 5-alpha-reductase activity GO:0047751 9.43 SRD5A2 SRD5A1
13 hormone activity GO:0005179 9.43 PRL POMC INHA GNRH1 CGB5 CGA
14 estrogen response element binding GO:0034056 9.4 ESR2 ESR1
15 steroid binding GO:0005496 9.17 SHBG PGR NR3C2 ESR2 ESR1 CYP3A4

Sources for Gynecomastia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....